Fulcrum Therapeutics Inc. (FULC) Announces Interim Analysis Data from its ReDUX4 Trial in FSHD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Fulcrum Therapeutics Inc. (FULC) Announces Interim Analysis Data from its ReDUX4 Trial in FSHD

Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 12c

August 11, 2020 7:08 AM EDT

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.66), $0.12 better than the analyst estimate of ($0.78).

The team at Fulcrum not only delivered key progress across our pipeline this quarter, but also expanded our work into additional areas of critical unmet need, said Robert J. Gould, Ph.D., president and chief executive... More